442 Littlefield Avenue
South San Francisco
About Blade Therapeutics
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Blade’s novel target biology was discovered by its founder, Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University. Blade licensed intellectual property associated with Dr. Dietz’s work and is advancing new compounds to halt the progression of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. By targeting novel pathways common to multiple fibrotic disease states, we believe we can build the leading company in anti-fibrotic drug discovery and development.
CEO: Wendye Robbins, M.D.
Please click here for Blade Therapeutics job opportunities.
43 articles about Blade Therapeutics
Blade Therapeutics Expands Leadership Team As Company Advances R&D Pipeline Addressing Fibrotic Diseases
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.